Liam Thompson explores some unconventional and interesting alternatives to the traditional alarm clock. Homes and buildings ...

Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed as shares slump 50% in ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Novo Nordisk, the company that makes Wegovy and Ozempic, is abruptly ousting its chief executive over concerns the firm is losing ground in the popular weight-loss drug market. The firm's market value ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.View on euronews ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

Imperial Brands said CEO Stefan Bomhard will retire after five years in the job, sending the British cigarette maker's shares ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

For everything that was wrong about WeightWatchers, once upon a time it did something right. It tapped into the power of ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.